UCB Completes Institutional Eurobond Offering

Brussels (Belgium), 23 March 2021 – 20:00 CET

UCB SA/NV (Euronext: UCB) announces today that it has completed the offering of EUR 500 million senior unsecured bonds, due March 2028 (the “Bonds”), to be issued under its EUR 5 billion EMTN Programme.

The Bonds will be issued at 99.751 per cent on March 30, 2021 and will be redeemed at 100 per cent of their principal amount on March 30, 2028. They will bear interest at an annual rate of 1.000 per cent.

Consistent with UCB's prudent financial strategy, the Bonds are issued to strengthen its balance sheet by partly refinancing the term loan debt incurred in April 2020 in connection with the acquisition of Ra Pharmaceuticals, Inc., at attractive terms.

Sandrine Dufour, Chief Financial Officer, UCB, commented, “We are very pleased with the confidence investors have shown in us through their positive response to this bond offering. The success of this transaction underlines UCB's access to the debt capital markets and allows us to diversify our lender base and extend our debt maturity profile.”

The Bonds were placed with qualified institutional investors across Europe. The transaction was conducted by BNP Paribas, Crédit Agricole CIB and ING, acting as Global Coordinators and Active Joint Lead Managers and Commerzbank and SMBC Nikko, acting as Active Joint Lead Managers for the offering. BofA Securities, IMI - Intesa Sanpaolo, KBC Bank, Mizuho Securities and Wells Fargo Securities acted as Passive Joint Lead Managers. The Bonds are expected to be listed on the regulated market of Euronext Brussels.

This press release does not constitute an offer to sell or a solicitation to buy any securities, and the offer of the Bonds by UCB does not constitute a public offering.

For further information
Antje Witte, Investor Relations, UCB
T +32 2 559 9414, [email protected]

About UCB
UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people operating in more than 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news